Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase – Time to Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw strong trading volume on Friday . 6,325 shares changed hands during mid-day trading, an increase of 63% from the previous session’s volume of 3,885 shares.The stock last traded at $24.74 and had previously closed at $25.00.

Analysts Set New Price Targets

A number of research firms have issued reports on AAPG. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price objective on the stock. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a research note on Monday, November 24th. Oppenheimer initiated coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target for the company. Finally, BTIG Research began coverage on shares of Ascentage Pharma Group International in a report on Monday, November 10th. They issued a “buy” rating and a $50.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $48.40.

Ascentage Pharma Group International Stock Down 2.4%

The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. The business’s 50 day moving average price is $28.49 and its two-hundred day moving average price is $34.87.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several large investors have recently modified their holdings of AAPG. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International in the third quarter worth about $383,000. XY Capital Ltd grew its stake in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares in the last quarter. UBS Group AG grew its stake in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares in the last quarter. ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth $204,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Ascentage Pharma Group International during the third quarter valued at about $96,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.